Search research articles
Contact Us
Filters
Showing results (41-50 of 337) with videos related to
Page
of 34
Sort By:
Current Opinion in HIV and AIDS
|
May 31, 2013
Sieve analysis in HIV-1 vaccine efficacy trials
Paul T Edlefsen, Peter B Gilbert, Morgane Rolland
Biostatistics (Oxford, England)
|
August 21, 2007
The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy
Peter B Gilbert, Ian W McKeague, Yanqing Sun
Statistics in Medicine
|
April 3, 2016
Power/sample size calculations for assessing correlates of risk in clinical efficacy trials
Peter B Gilbert, Holly E Janes, Yunda Huang
Current Opinion in HIV and AIDS
|
September 24, 2016
Modeling HIV vaccine trials of the future
Peter B Gilbert, Ying Huang, Holly E Janes
Statistics in Medicine
|
January 14, 2009
Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'
Peter B Gilbert, Li Qin, Steven G Self
Lifetime Data Analysis
|
May 8, 2004
Tests for comparing mark-specific hazards and cumulative incidence functions
Peter B Gilbert, Ian W McKeague, Yanqing Sun
Statistics in Medicine
|
November 6, 2007
Evaluating a surrogate endpoint at three levels, with application to vaccine development
Peter B Gilbert, Li Qin, Steven G Self
Medrxiv : the Preprint Server for Health Sciences
|
January 27, 2021
Evaluating the Long-Term Efficacy of COVID-19 Vaccines
Dan-Yu Lin, Donglin Zeng, Peter B Gilbert
Biometrics
|
July 5, 2007
Genome scanning tests for comparing amino acid sequences between groups
Peter B Gilbert, Chunyuan Wu, David V Jobes
Journal of the American Statistical Association
|
January 6, 2009
Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization
Bryan E Shepherd, Peter B Gilbert, Thomas Lumley
Page
of 34
Search research articles
Search
Showing results (41-50 of 337) with videos related to
Sort By:
Page
of 34
Current Opinion in HIV and AIDS
|
May 31, 2013
Sieve analysis in HIV-1 vaccine efficacy trials
Paul T Edlefsen, Peter B Gilbert, Morgane Rolland
Biostatistics (Oxford, England)
|
August 21, 2007
The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy
Peter B Gilbert, Ian W McKeague, Yanqing Sun
Statistics in Medicine
|
April 3, 2016
Power/sample size calculations for assessing correlates of risk in clinical efficacy trials
Peter B Gilbert, Holly E Janes, Yunda Huang
Current Opinion in HIV and AIDS
|
September 24, 2016
Modeling HIV vaccine trials of the future
Peter B Gilbert, Ying Huang, Holly E Janes
Statistics in Medicine
|
January 14, 2009
Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'
Peter B Gilbert, Li Qin, Steven G Self
Lifetime Data Analysis
|
May 8, 2004
Tests for comparing mark-specific hazards and cumulative incidence functions
Peter B Gilbert, Ian W McKeague, Yanqing Sun
Statistics in Medicine
|
November 6, 2007
Evaluating a surrogate endpoint at three levels, with application to vaccine development
Peter B Gilbert, Li Qin, Steven G Self
Medrxiv : the Preprint Server for Health Sciences
|
January 27, 2021
Evaluating the Long-Term Efficacy of COVID-19 Vaccines
Dan-Yu Lin, Donglin Zeng, Peter B Gilbert
Biometrics
|
July 5, 2007
Genome scanning tests for comparing amino acid sequences between groups
Peter B Gilbert, Chunyuan Wu, David V Jobes
Journal of the American Statistical Association
|
January 6, 2009
Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization
Bryan E Shepherd, Peter B Gilbert, Thomas Lumley
Page
of 34